| CAS NO: | 223568-55-6 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 223568-55-6 |
| 别名 | F1013 |
| Canonical SMILES | O=C(O)C[C@H](NC([C@H](C(C)C)NC(OCC1=CC=CC=C1)=O)=O)C(CF)=O |
| 分子式 | C18H23FN2O6 |
| 分子量 | 382.38 |
| 溶解度 | DMSO : ≥ 60 mg/mL (156.91 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | EP1013 is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes. EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversalrate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function[1]. [1]. Emamaullee JA, et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes. 2008 Jun;57(6):1556-66. |
m.cnreagent.com